CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home » NEWS

Oncology NEWS International. Vol. 10 No. 11
Pages: 1  2  3  
Next
 

Memory T Cells in Bone Marrow Can Fight Tumors

November 1, 2001

HEIDELBERG—A "proof of concept" study from researchers at the German Cancer Research Center shows that tumor-reactive memory T cells already present in the bone marrow of many cancer patients can be mobilized, restimulated, and deployed against the individual’s own breast, ovarian, or cervical tumor.

The research team, led by Drs. Volker Schirrmacher, Markus Feuerer, and Victor Umansky, think that cells from cancer patients’ own bone marrow might be activated by individualized tumor vaccines ex vivo and then be given back to the patient where they should attack tumor deposits through a "graft-vs-tumor" effect without reacting against normal cells.

A paper detailing the breast cancer data and published in Nature Medicine showed that breast cancer patients store tumor-reactive T cells in their bone marrow and that T cells from most patients can be reactivated into cytotoxic effector cells that will destroy the "parent" tumor xenotransplanted into NOD/SCID mice.

Similar memory cells exist in the peripheral blood but could not be reactivated into effector cells. The marrow memory cells are exquisitely specific. They responded only to lysates of tumor cells, not to preparations from normal cells.

Professor Schirrmacher told ONI that a single dose containing 5,000,000 × 10³ T cells and 1,000,000 × 10³ autologous dendritic cells was enough to produce "a strong, long-lasting graft-vs-tumor reactivity" and reduce the tumor to only its stromal scaffolding.

Tumor regression was associated with infiltration by human T cells, apoptosis of tumor cells, and tumor necrosis. Dr. Schirrmacher is head of the Cellular Immunology Laboratory at the German Cancer Research Center, Heidelberg.

"Based on experimental studies in animals, we had predicted in 1994 that the bone marrow might be a special compartment for immunological memory and tumor dormancy," Dr. Schirrmacher said. "We decided to test this in humans and investigate bone marrow from cancer patients, but we did not expect the results to provide so much support for our original idea."

Pages: 1  2  3  
Next
 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.






 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
FROM PHYSICIANS PRACTICE
Key Differences between FQHCs and RHCs
Chastity Werner, RHIT, June 13, 2013
FQHCs and RHCs take up a unique niche among physician practices. And that affects compensation and billing.
Improving Care Coordination in Your Practice
Susanne Madden,  June 12, 2013
Practices are feverishly working to control the rising costs of healthcare - effective care coordination can help.
Refunding Overpayments: Two Options for Medical Practices
Ericka L. Adler,  June 12, 2013
Medicare and Medicaid providers must return overpayments once identified. Here are two different refund approaches for practices to consider when necessary.
Four Easy Ways to Boost Patient Time of Service Collections
Aubrey Westgate,  June 12, 2013
Simple ways your medical practice staff can increase the likelihood patients will pay when presenting for appointments.
iPad Alternatives for Mobile Physicians
Marisa Torrieri, June 11, 2013
As more physicians are seeing the merits of media tablets, the market is expanding, too.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Papillary Thyroid Carcinoma
  • Robotic-Assisted Radical Prostatectomy: Who Is Benefiting?
  • ASCO: Long-Term Tamoxifen Benefit for Breast Cancer Confirmed
  • Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
  • Cannabis Linked to Decreased Bladder Cancer Risk
  • Breast Cancer Screening, Risk, and Options for High-Risk Women
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Rising PSA Level in a 46-Year-Old Man
  • ASCO: Long-Term Tamoxifen Benefit for Breast Cancer Confirmed
  • Bladder Cancer Recurrence High, Better Follow-Up Care Needed
  • ASCO: Post-Surgery Surveillance Found Safe in Seminoma
  • Fertility Preservation in Women With Breast Cancer: Challenges and Opportunities
  • Addressing Fertility Concerns in Women Diagnosed With Breast Cancer: Will Serial Reserve Screening Help?
  • Postmenopausal Hormone Receptor–Positive Advanced Breast Cancer
Click here to subscribe to our newsletter


CancerNetwork on Facebook


CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy